AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12584783 — intervention group
Group type: EXPERIMENTAL
Intervention: Yizhi mixture (YZM)
Number of subjects: 210
Study 12584783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritalin
Number of subjects: 210
Study 12584783 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of YZM and Ritalin
Number of subjects: 210
Study 10600792 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 10600792 — intervention group
Group type: COMPARATOR
Intervention: hCG
Number of subjects: 0
Study 7717739 — intervention group
Group type: EXPERIMENTAL
Intervention: Viable L casei strain GG
Number of subjects: 25
Study 7717739 — intervention group
Group type: COMPARATOR
Intervention: Inactivated L casei strain GG
Number of subjects: 25
Study 1843963 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) solution administered at a rate of 0.5 liters daily for 8 days (Group 1: placebo first week, PEG second week)
Number of subjects: 34
Study 1843963 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) solution administered at a rate of 0.5 liters daily for 8 days (Group 2: PEG first week, placebo second week)
Number of subjects: 34
Study 1843963 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG) solution
Number of subjects: 34
Study 6754062 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine 1 mg/m2, doxorubicin 40 mg/m2 on day one and cyclophosphamide 200 mg/m2 orally days 3‐6 (VAC)
Number of subjects: 81
Study 6754062 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide 350 mg/m2, methotrexate 20 mg/m2, and 5‐fluorouracil 350 mg/m2 (CMF) intravenously
Number of subjects: 81
Study 6754062 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC
Number of subjects: 81
Study 6754062 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 81
Study 6754062 — intervention group
Group type: COMPARATOR
Intervention: VAC and CMF
Number of subjects: 81
Study 29392787 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarolaner
Number of subjects: 241
Study 29392787 — intervention group
Group type: COMPARATOR
Intervention: Moxidectin/imidacloprid
Number of subjects: 241
Study 29392787 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 241
Study 26447868 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-holding (BH) high-pitch helical CTPA
Number of subjects: 99
Study 26447868 — intervention group
Group type: COMPARATOR
Intervention: Free-breathing (FB) high-pitch helical CTPA
Number of subjects: 99
Study 24503205 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 30
Study 24503205 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 30
Study 22301077 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant use (SSRIs and TCAs)
Number of subjects: 6998
Study 22301077 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed users of antidepressants
Number of subjects: 6998
Study 22301077 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-depressed users of antidepressants
Number of subjects: 6998
Study 22301077 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed non-users of antidepressants
Number of subjects: 6998
Study 22301077 — intervention group
Group type: COMPARATOR
Intervention: All three groups (depressed users, non-depressed users, depressed non-users)
Number of subjects: 6998
Study 20236108 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted radical vaginal hysterectomy (LARVH)
Number of subjects: 15
Study 20236108 — intervention group
Group type: COMPARATOR
Intervention: Radical abdominal hysterectomy (RAH)
Number of subjects: 15
Study 18343254 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 4 mg/kg i.v. followed by infusion of 150 microg/kg x min(‐1)
Number of subjects: 88
Study 18343254 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane 8% by face mask followed by sevoflurane 1.5%
Number of subjects: 88
Study 15839438 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-Inhibition-Module (LIM)
Number of subjects: 14
Study 15839438 — intervention group
Group type: COMPARATOR
Intervention: Control (no LIM)
Number of subjects: 14
Study 12417881 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-IgE + SIT-grass (n = 23)
Number of subjects: 92
Study 12417881 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-IgE + SIT-birch (n = 23)
Number of subjects: 92
Study 12417881 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-IgE + SIT-grass
Number of subjects: 92
Study 12417881 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-IgE + SIT-birch
Number of subjects: 92
Study 10754735 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (t-PA)
Number of subjects: 44
Study 10754735 — intervention group
Group type: EXPERIMENTAL
Intervention: No thrombolytic therapy
Number of subjects: 44
Study 10754735 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinically healthy individuals)
Number of subjects: 44
Study 8815395 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose thiamine supplementation (100 mg/day)
Number of subjects: 16
Study 8815395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1507325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystoscopically placed cobra catheter for directed irrigation during ESWL
Number of subjects: 45
Study 1507325 — intervention group
Group type: COMPARATOR
Intervention: Randomly selected controls (no cobra catheter)
Number of subjects: 45
Study 6436874 — intervention group
Group type: EXPERIMENTAL
Intervention: Single night-time dose of trazodone (100-400 mg)
Number of subjects: 56
Study 6436874 — intervention group
Group type: COMPARATOR
Intervention: Divided daily doses of trazodone (100-400 mg)
Number of subjects: 56
Study 31425658 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus Retraining Therapy (TRT)
Number of subjects: 0
Study 31425658 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care Control Condition
Number of subjects: 0
Study 28853228 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day Anagliptin (ANA) for 24 weeks
Number of subjects: 87
Study 28853228 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day Anagliptin (ANA) for 12 weeks
Number of subjects: 87
Study 28853228 — intervention group
Group type: COMPARATOR
Intervention: 25 mg/day Alogliptin (ALO) for 24 weeks
Number of subjects: 87
Study 26458536 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination uridine triphosphate (UTP), cytidine monophosphate (CMP), and hydroxycobalamin (vitamin B12)
Number of subjects: 12
Study 26458536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1435847 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ketoconazole shampoo
Number of subjects: 176
Study 1435847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 22614767 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline 5% (HS) (n = 16)
Number of subjects: 41
Study 22614767 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) (n = 25)
Number of subjects: 41
Study 22614767 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study 20116296 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV risk reduction program (four 2-hour sessions at community-based locations)
Number of subjects: 744
Study 18332159 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest third of Vo(2max)
Number of subjects: 1347
Study 18332159 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle third of Vo(2max)
Number of subjects: 1347
Study 15758755 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin (30 mg once daily)
Number of subjects: 67
Study 15758755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 12724019 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin therapy (500 mg three times a day for 8 weeks)
Number of subjects: 40
Study 10593775 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy (2 L/min by nasal cannula)
Number of subjects: 25
Study 10593775 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal CPAP therapy (9 +/- 0.3 cm H(2)O)
Number of subjects: 25
Study 8726183 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by chemotherapy (29 patients)
Number of subjects: 75
Study 8726183 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy followed by surgery and chemotherapy (21 patients)
Number of subjects: 75
Study 8726183 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (25 patients)
Number of subjects: 75
Study 2069188 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic reflex testing using sinusoidal bursts of 125, 500, 1,000, and 2,000 Hz stimuli
Number of subjects: 21
Study 6150185 — intervention group
Group type: EXPERIMENTAL
Intervention: Various scavengers of free radicals of the oxygen species
Number of subjects: 0
Study 6150185 — intervention group
Group type: COMPARATOR
Intervention: Dithranol (anthralin)
Number of subjects: 0
Study 31908843 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept in combination with methotrexate
Number of subjects: 0
Study 31908843 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with methotrexate
Number of subjects: 0
Study 30184096 — intervention group
Group type: EXPERIMENTAL
Intervention: Education + Self‐Regulation intervention
Number of subjects: 54
Study 30184096 — intervention group
Group type: COMPARATOR
Intervention: Education Only condition
Number of subjects: 54
Study 26723110 — intervention group
Group type: EXPERIMENTAL
Intervention: Long interval (6 to 8 weeks) between neoadjuvant radiation therapy and surgery
Number of subjects: 210
Study 26723110 — intervention group
Group type: COMPARATOR
Intervention: Short interval (2 weeks) between neoadjuvant radiation therapy and surgery
Number of subjects: 210
Study 26723110 — intervention group
Group type: EXPERIMENTAL
Intervention: Long interval (6 to 8 weeks)
Number of subjects: 210
Study 26723110 — intervention group
Group type: COMPARATOR
Intervention: Short interval (2 weeks)
Number of subjects: 210
Study 26723110 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 210
Study 23263694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic intervention program including comprehensive ergonomic training, two interactive sessions, an ergonomic training brochure, and workplace visits with workstation adjustments.
Number of subjects: 94
Study 23263694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic intervention program
Number of subjects: 94
Study 23263694 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ergonomic intervention)
Number of subjects: 94
Study 22267768 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9668 (60 mg twice daily orally for 4 weeks)
Number of subjects: 56
Study 22267768 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9668
Number of subjects: 56
Study 22267768 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 56
Study 20874829 — intervention group
Group type: EXPERIMENTAL
Intervention: Astra Tech® implants (n=24)
Number of subjects: 18
Study 20874829 — intervention group
Group type: EXPERIMENTAL
Intervention: Brånemark® implants (n=23)
Number of subjects: 18
Study 20874829 — intervention group
Group type: COMPARATOR
Intervention: Both implant systems
Number of subjects: 18
Study 17696673 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week cognitive-behavioral group
Number of subjects: 91
Study 17696673 — intervention group
Group type: COMPARATOR
Intervention: 16-week supportive/exploratory group
Number of subjects: 91
Study 17696673 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment conditions
Number of subjects: 91
Study 17979957 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team care in community hospitals
Number of subjects: 490
Study 17979957 — intervention group
Group type: COMPARATOR
Intervention: General hospital care
Number of subjects: 490
Study 15526837 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 11225459 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Lavasept solution
Number of subjects: 80
Study 11225459 — intervention group
Group type: COMPARATOR
Intervention: Ringer solution
Number of subjects: 80
Study 9311442 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR-CH (aclarubicin adsorbed on activated carbon particles)
Number of subjects: 30
Study 9311442 — intervention group
Group type: COMPARATOR
Intervention: ACR-AQ (aclarubicin aqueous solution)
Number of subjects: 30
Study 8055500 — intervention group
Group type: EXPERIMENTAL
Intervention: Counter-rotational toothbrush (INTERPLAK Home Plaque‐Removal Instrument)
Number of subjects: 32
Study 8055500 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 32
Study 3522311 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 1800 mg
Number of subjects: 46
Study 3522311 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 2400 mg
Number of subjects: 46
Study 3522311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 31196113 — intervention group
Group type: EXPERIMENTAL
Intervention: Thawed frozen embryo transfer
Number of subjects: 0
Study 31196113 — intervention group
Group type: COMPARATOR
Intervention: Fresh embryo transfer
Number of subjects: 0
Study 28097356 — intervention group
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Number of subjects: 683
Study 28097356 — intervention group
Group type: COMPARATOR
Intervention: Cinacalcet
Number of subjects: 683
Study 25856450 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly or biweekly visits from an educator
Number of subjects: 0
Study 25856450 — intervention group
Group type: COMPARATOR
Intervention: In-services only
Number of subjects: 0
Study 24117970 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma
Number of subjects: 2168
Study 24117970 — intervention group
Group type: COMPARATOR
Intervention: Well-controlled asthma
Number of subjects: 2168
Study 21390976 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused meditation with eye-closure technique
Number of subjects: 0
Study 21390976 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused meditation with context reinstatement
Number of subjects: 0
Study 21390976 — intervention group
Group type: COMPARATOR
Intervention: Context reinstatement
Number of subjects: 0
Study 20026533 — intervention group
Group type: EXPERIMENTAL
Intervention: Figure-of-8 suturing
Number of subjects: 195
Study 20026533 — intervention group
Group type: COMPARATOR
Intervention: Interrupted sutures
Number of subjects: 195
Study 17087951 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil 10 mg once daily for 48 weeks, followed by adefovir dipivoxil from week 49 to 96, and then open-label for up to 240 weeks.
Number of subjects: 125
Study 17087951 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil treatment for up to 240 weeks.
Number of subjects: 125
Study 15008726 — intervention group
Group type: EXPERIMENTAL
Intervention: ProstaLund Feedback Treatment (PLFT)
Number of subjects: 146
Study 15008726 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 146
Study 15008726 — intervention group
Group type: EXPERIMENTAL
Intervention: ProstaLund Feedback Treatment (PLFT) and Transurethral resection of the prostate (TURP)
Number of subjects: 146
Study 11123371 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS‐S patch + 0.6 mg of scopolamine per os (p.o.)
Number of subjects: 25
Study 11123371 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS‐S patch + 0.3 mg of scopolamine p.o.
Number of subjects: 25
Study 11123371 — intervention group
Group type: COMPARATOR
Intervention: TTS‐S patch + placebo tablet
Number of subjects: 25
Study 9678812 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg plus clarithromycin 250 mg and tinidazole 500 mg (RBCCT)
Number of subjects: 157
Study 9678812 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg plus clarithromycin 500 mg and amoxycillin 1 g (RBCCA)
Number of subjects: 157
Study 9678812 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg plus tinidazole 500 mg and amoxycillin 1 g (RBCTA)
Number of subjects: 157
Study 8205581 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Platinum Professional Toothwhitening System
Number of subjects: 38
Study 8205581 — intervention group
Group type: COMPARATOR
Intervention: Rembrandt Lighten Bleaching Gel
Number of subjects: 38
Study 2645466 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (oral bacille Calmette‐Guérin [BCG] 120 mg once a month for 5 years)
Number of subjects: 253
Study 2645466 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (oral BCG 120 mg once a month for 5 years with meCCNU 130 mg/m2 on day 1 and 5-FU 325 mg/m2/day on days 1-5 and 375 mg/m2/day on days 36-40, repeated every 10 weeks for 8 cycles)
Number of subjects: 253
Study 2645466 — intervention group
Group type: COMPARATOR
Intervention: Control (no further therapy after surgery)
Number of subjects: 253
Study 30339194 — intervention group
Group type: EXPERIMENTAL
Intervention: ramucirumab+FOLFIRI
Number of subjects: 1072
Study 28103611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 100 mg daily during a 12-week lead-in
Number of subjects: 77
Study 28103611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 28103611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 77
Study 25855679 — intervention group
Group type: EXPERIMENTAL
Intervention: No/Trace TR (n=167)
Number of subjects: 542
Study 25855679 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild TR (n=205)
Number of subjects: 542
Study 25855679 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate TR (n=117)
Number of subjects: 542
Study 25855679 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe TR (n=18)
Number of subjects: 542
Study 25855679 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe TR
Number of subjects: 542
Study 25855679 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate TR
Number of subjects: 542
Study 25855679 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrial and RV enlargement
Number of subjects: 542
Study 25855679 — intervention group
Group type: EXPERIMENTAL
Intervention: RV dysfunction
Number of subjects: 542
Study 25855679 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between TR and mitral regurgitation severity
Number of subjects: 542
Study 22592176 — intervention group
Group type: EXPERIMENTAL
Intervention: Handled medicine ball (HMB) throws included in the regular tennis practice
Number of subjects: 44
Study 22592176 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweighted racket (OWR) during regular tennis practice
Number of subjects: 44
Study 22592176 — intervention group
Group type: COMPARATOR
Intervention: Regular tennis training (RTT)
Number of subjects: 44
Study 21757667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue-type plasminogen activator (tPA) at a total dose of 0.9 mg/kg, with 10% given as a 1-minute bolus and the remainder over 1 hour
Number of subjects: 8
Study 21757667 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (placebo)
Number of subjects: 8
Study 19728370 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg
Number of subjects: 294
Study 19728370 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 5 mg
Number of subjects: 294
Study 16752076 — intervention group
Group type: EXPERIMENTAL
Intervention: High telomere content (TC >123% of standard)
Number of subjects: 210
Study 16752076 — intervention group
Group type: COMPARATOR
Intervention: Low telomere content (TC <101% of standard)
Number of subjects: 210
Study 16752076 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curves using TC thresholds
Number of subjects: 210
Study 15146393 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy initiation
Number of subjects: 140
Study 15146393 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy completion
Number of subjects: 140
Study 15146393 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in psychopathology
Number of subjects: 140
Study 15146393 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in interpersonal problems
Number of subjects: 140
Study 15146393 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective experience of symptoms
Number of subjects: 140
Study 15146393 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy outcome comparison
Number of subjects: 140
Study 11713616 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 11713616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9429271 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated off-line AMMA-signal analysis system using selected features extracted from input data
Number of subjects: 11
Study 9429271 — intervention group
Group type: COMPARATOR
Intervention: Artificial neural network method
Number of subjects: 11
Study 8508462 — intervention group
Group type: COMPARATOR
Intervention: Sabeluzole 2 x 10 mg/d
Number of subjects: 56
Study 8508462 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabeluzole 3 x 10 mg/d
Number of subjects: 56
Study 2832178 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus 600 cGy of both upper and lower half-body irradiation
Number of subjects: 96
Study 2832178 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 96
Study 29668918 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride (0.5 mg/kg)
Number of subjects: 36
Study 29668918 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 36
Study 28034967 — intervention group
Group type: EXPERIMENTAL
Intervention: Online interactive continuing education (CE) program for primary care providers (PCPs)
Number of subjects: 238
Study 28034967 — intervention group
Group type: COMPARATOR
Intervention: Control condition (online, text‐based CE program)
Number of subjects: 238
Study 25557468 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (pre-CRT) followed by esophagectomy
Number of subjects: 49
Study 25557468 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET scan after pre-CRT
Number of subjects: 49
Study 25557468 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔSUV
Number of subjects: 49